Answers are grounded in this paper and cite their sources.
Background Transgender and gender diverse (TGD) people comprise 0.5–1% of the population. They face unique cancer risks, shaped by gender-affirming care (GAC) and barriers to screening and treatment. However, there is no robust data on cancer burden in TGD people. Using publicly available data, we aimed to estimate the annual number of cancer cases in TGD people in England, by gender, age group, tumour type and current/planned GAC, and to project cases at 5 and 10 years. Methods In this modelling study, we combined data from 2023 cancer surveillance data, Census 2021 population counts, the proportion of TGD people from the 2025 General Practice Patient Survey, and survey-based 2025 GAC access. The main outcome was the expected annual number of cancer cases in England, estimated using age-stratified Monte Carlo simulations with 95% uncertainty intervals (UI). Cases at 5 and 10 years were projected with NORDPRED using 2004–2023 incidence data. Findings The estimated TGD population in England is 441,547 (95% UI 429,207–452,980). We estimated 965 (95% UI 879–1070) annual cases in TGD people, excluding non-melanoma skin cancer. The predominant cancers in TGD people are breast (19%, n=187, 95% UI 149–241), colorectal (12%, n=117, 95% UI 106–129), and lung (11%, n=108, 95% UI 96–122). Cases in TGD people are projected to increase to 1739 (95% UI 1582–1938) in 5 years and 2257 (95% UI 2063–2508) in 10 years (excluding non-melanoma skin cancer). If TGD people could access their planned GAC, this would reduce to 1549 (95% UI 1354–1802) and 2006 (95% UI 1758–2339) respectively. Interpretation To our knowledge, this is the first prediction of cancer cases in TGD people in England. Our estimations support the need for service planning and oncology training. With the TGD population ageing and unmet GAC needs, cancer cases in TGD people will more than double within a decade, with direct adverse health consequences and economic implications. Appropriate recording of sex characteristics, gender identity and gender incongruence in electronic health systems and cancer registries is needed to validate these results. Funding This project received no direct funding. Dr Berner's salary was funded by an NIHR Advanced Fellowship (Award ID NIHR306560).
No takes yet. Share an insight, caveat, or question.
Pasin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: